Bush's Science Budget: Will It Hold?

The president's financial plan looks good on paper, but Congress now faces the tough job of reconciling promises with harsh reality. WASHINGTON--Benjamin Franklin, the story goes, was asked what he and his fellow statesmen had produced during their deliberations in that steamy Philadelphia summer of 1776. "A republic," he answered, "if you can keep it." Every federal budget raises anew the question of whether a large increase sought for any one program will come at the expense of other pro

Written byJeffrey Mervis
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

WASHINGTON--Benjamin Franklin, the story goes, was asked what he and his fellow statesmen had produced during their deliberations in that steamy Philadelphia summer of 1776. "A republic," he answered, "if you can keep it." Every federal budget raises anew the question of whether a large increase sought for any one program will come at the expense of other programs. For scientists, the issue is best symbolized this year by the supercollider, for which the administration wants $300 million more on the road to completing the $8.25 billion facility in 1999. Administration officials say they have adhered to a promise to scientists that the 54-mile-long proton-proton accelerator will not drain funds from other research projects, both within the Energy Department and throughout the government. But many analysts express disbelief at such claims, pointing to the discrepancy between the sharp rise in SSC funding and the essentially flat level of spending within ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies